SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (320)11/2/2005 12:20:27 PM
From: NeuroInvestment   of 362
 
Erik:

While I don't completely agree with some of the presuppositions, your conclusion makes some sense. Richard Allen developed Spheramine via his company Theracell, and he knows that program better than anyone else at Titan. He and Victor Bauer were both at Hoechst Marion-Roussel, which initially developed iloperidone--it was Bauer who was more involved with iloperidone, I tended to talk to Bauer about that program way back when--but Allen obviously is well-connected there too. There isn't much obvious overlap between Vanda and Hoechst, only Vanda's Manufacturing head. Vanda is mainly built around Novartis alumni.

But your conclusion that iloperidone would be the likely point of leverage makes sense--it's the only program with that kind of demonstable potential. The caveat is: even if Vanda can identify QTc vulnerable patients, how do they do so, and is it applicable to governmentally underfunded programs for the chronic mentally ill?
If it is something observable on an EKG, few if any psychiatrists are going to attempt to screen EKGs for eligibility, and clinics don't have other physicians on staff. Maybe a nurse practitioner, but the liability risks would be intimidating. Genetic testing? Forget it.

Excellent sleuthing on your part to catch these insider buys, and it is hard to imagine that they are not due to something tangible: between Spheramine and iloperidone, iloperidone is the more obvious commercial possibility....

Harry
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News